Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.

Martora, Fabrizio; Scalvenzi, Massimiliano; Battista, Teresa; Fornaro, Luigi; Potestio, Luca; Ruggiero, Angelo; Megna, Matteo

Martora, Fabrizio; Scalvenzi, Massimiliano; Battista, Teresa; Fornaro, Luigi; Potestio, Luca; Ruggiero, Angelo; Megna, Matteo.

Afiliación

Martora F; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Scalvenzi M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Battista T; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Fornaro L; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Potestio L; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Ruggiero A; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Clin Cosmet Investig Dermatol ; 16: 2525-2536, 2023.

Article en En | MEDLINE | ID: mdl-37745273

Palabras clave

anti-IL23; guselkumab; hidradenitis suppurativa; real life evidence; risankizumab; tildrakizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Clin Cosmet Investig Dermatol Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google